Literature DB >> 11148054

Conformational origin of the aggregation of recombinant human factor VIII.

A O Grillo1, K L Edwards, R S Kashi, K M Shipley, L Hu, M J Besman, C R Middaugh.   

Abstract

Aggregation of proteins is a major problem in their use as drugs and is also involved in a variety of pathological diseases. In this study, biophysical techniques were employed to investigate aggregate formation in the pharmaceutically important protein, recombinant human factor VIII (rhFVIII). Recombinant human factor VIII incubated in solution at 37 degrees C formed soluble aggregates as detected by molecular sieve chromatography and dynamic light scattering. This resulted in a corresponding loss of biological activity. Fluorescence and CD spectra of the thermally stressed rhFVIII samples did not, however, suggest significant differences in protein conformation. To identify conformational changes in rhFVIII that may be involved in rhFVIII aggregation, temperature and solutes were used to perturb the native structure of rhFVIII. Far-UV CD and FTIR studies of rhFVIII as a function of temperature revealed conformational changes corresponding to an increase in intermolecular beta-sheet content beginning at approximately 45 degrees C with significant aggregation observed above 60 degrees C. Fluorescence and DSC studies of rhFVIII also indicated conformational changes initiating between 45 and 50 degrees C. An increase in the exposure of hydrophobic surfaces was observed beginning at approximately 40 degrees C, as monitored by increased binding of the fluorescent probe, bis-anilinonaphthalene sulfonic acid (bis-ANS). Perturbation by various solutes produced several transitions prior to extensive unfolding of rhFVIII. In all cases, a common transition, characterized by an increase in the wavelength of the fluorescence emission maximum of rhFVIII from approximately 330 to 335 nm, was observed during thermal and solute perturbation of factor VIII. Moreover, this transition was correlated with an increased association of factor VIII upon incubation at 37 degrees C in the presence of various solutes. These results suggest that association of rhFVIII in solution was initiated by a small transition in the tertiary structure of the protein which produced a nucleating species that led to the formation of inactive soluble aggregates.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11148054     DOI: 10.1021/bi001547t

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  21 in total

Review 1.  Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation.

Authors:  Eva Y Chi; Sampathkumar Krishnan; Theodore W Randolph; John F Carpenter
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

2.  Correlation of rFVIII inactivation with aggregation in solution.

Authors:  Wei Wang; Drew N Kelner
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

3.  Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice.

Authors:  Vivek S Purohit; C Russell Middaugh; Sathyamangalam V Balasubramanian
Journal:  J Pharm Sci       Date:  2006-02       Impact factor: 3.534

4.  Nonnative protein polymers: structure, morphology, and relation to nucleation and growth.

Authors:  William F Weiss; Travis K Hodgdon; Eric W Kaler; Abraham M Lenhoff; Christopher J Roberts
Journal:  Biophys J       Date:  2007-08-17       Impact factor: 4.033

Review 5.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

6.  Aggregation stability of a monoclonal antibody during downstream processing.

Authors:  Paolo Arosio; Giuliano Barolo; Thomas Müller-Späth; Hua Wu; Massimo Morbidelli
Journal:  Pharm Res       Date:  2011-03-30       Impact factor: 4.200

7.  Controlling the aggregation and rate of release in order to improve insulin formulation: molecular dynamics study of full-length insulin amyloid oligomer models.

Authors:  Workalemahu Mikre Berhanu; Artëm E Masunov
Journal:  J Mol Model       Date:  2011-06-15       Impact factor: 1.810

8.  Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex.

Authors:  Vivek S Purohit; Karthik Ramani; Rita Sarkar; Haig H Kazazian; Sathyamangalam V Balasubramanian
Journal:  J Biol Chem       Date:  2005-02-23       Impact factor: 5.157

9.  Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo.

Authors:  Matthew P Kosloski; Krithika A Shetty; Hironao Wakabayashi; Philip J Fay; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2014-06-17       Impact factor: 4.009

10.  Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII.

Authors:  Matthew P Kosloski; Razvan D Miclea; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2009-06-05       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.